ARTV · Why this verdict
Why Artiva Biotherapeutics (ARTV) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.4/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Artiva Biotherapeutics is a pre-revenue biotech with quality metrics below the engine's floor and a rejected analyst target, but heavy recent insider buying and a technical breakout offer a bullish counter-signal.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Artiva's quality score of 1.6 sits far below the engine's 4.0 floor, reflecting zero gross, operating, and net margins and no competitive moat. Quality breakdown | The quality score improves toward the 4.0 floor as revenue-generating programs progress. | →Stable |
| CounterPre-revenue biotech companies routinely score near zero on margin-based quality metrics regardless of pipeline value, so this signal may say little about the actual investment case. | ||
Insiders have bought $128.3 million of stock, equal to 27.5% of market cap, over the trailing 90 days, and the insider signal reads BULLISH. Insider | The insider signal stays BULLISH or shows continued net buying over the next few quarters. | →Stable |
| CounterA single large insider purchase, such as a PIPE or founder round, can dominate the 90-day window and may not reflect broad-based conviction buying from multiple insiders. | ||
The stock is in a golden-cross breakout above all moving averages with RSI 64 and bullish MACD, per the engine's setup rationale. Chart pattern detection | The momentum score, currently 6.7, stays above the 5.5 threshold as the breakout continues. | →Stable |
| CounterThe asymmetry gate flags upside as exhausted at 0%, meaning the technical breakout has already run into the stock's resistance-based take-profit level with no further modeled room. | ||
The analyst target of $35.80 was rejected as implausible, at 3.7x the $9.61 spot price, forcing a fallback to a technical take-profit with 0% modeled upside. Warnings | A credible, non-implausible analyst target reemerges, or the technical resistance level rises to restore positive modeled upside. | ↓Deteriorating |
| CounterA data-quality rejection of an analyst target does not necessarily mean the target is wrong; if legitimate, actual upside could be far larger than the model currently allows for. | ||
The company has missed earnings estimates in each of its last 3 reported quarters, with an average surprise of roughly -9%, per the earnings history. Earnings | The miss streak breaks and the company beats or meets estimates in upcoming quarters. | →Stable |
| CounterConsistent misses at a clinical-stage biotech are less meaningful than at a company with a mature revenue base, since reported 'earnings' here largely reflect R&D spend timing rather than a demand signal. | ||
Artiva's quality score of 1.6 sits far below the engine's 4.0 floor, reflecting zero gross, operating, and net margins and no competitive moat.
→StableQuality breakdown
- Expectation
- The quality score improves toward the 4.0 floor as revenue-generating programs progress.
CounterPre-revenue biotech companies routinely score near zero on margin-based quality metrics regardless of pipeline value, so this signal may say little about the actual investment case.
Insiders have bought $128.3 million of stock, equal to 27.5% of market cap, over the trailing 90 days, and the insider signal reads BULLISH.
→StableInsider
- Expectation
- The insider signal stays BULLISH or shows continued net buying over the next few quarters.
CounterA single large insider purchase, such as a PIPE or founder round, can dominate the 90-day window and may not reflect broad-based conviction buying from multiple insiders.
The stock is in a golden-cross breakout above all moving averages with RSI 64 and bullish MACD, per the engine's setup rationale.
→StableChart pattern detection
- Expectation
- The momentum score, currently 6.7, stays above the 5.5 threshold as the breakout continues.
CounterThe asymmetry gate flags upside as exhausted at 0%, meaning the technical breakout has already run into the stock's resistance-based take-profit level with no further modeled room.
The analyst target of $35.80 was rejected as implausible, at 3.7x the $9.61 spot price, forcing a fallback to a technical take-profit with 0% modeled upside.
↓DeterioratingWarnings
- Expectation
- A credible, non-implausible analyst target reemerges, or the technical resistance level rises to restore positive modeled upside.
CounterA data-quality rejection of an analyst target does not necessarily mean the target is wrong; if legitimate, actual upside could be far larger than the model currently allows for.
The company has missed earnings estimates in each of its last 3 reported quarters, with an average surprise of roughly -9%, per the earnings history.
→StableEarnings
- Expectation
- The miss streak breaks and the company beats or meets estimates in upcoming quarters.
CounterConsistent misses at a clinical-stage biotech are less meaningful than at a company with a mature revenue base, since reported 'earnings' here largely reflect R&D spend timing rather than a demand signal.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 3.9 |
| OBV | 9.3 |
| MA position | 9.0 |
| Volume | 3.7 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 258%
Insider
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 9.0 |
| insider conviction | 6.2 |
| holder change | 0.5 |
| notable moves | 3.0 |
- ▸Heavy insider buying — $128,466,079 (28.896% of mkt cap)
- ▸Institutions reducing
Peer rank
4.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 1.4 |
| growth rank | 5.0 |
Technical
2.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.0 |
| support resistance | 1.5 |
| 52w position | 3.8 |
| gap | 3.0 |
- ▸Extreme gap up (6.9%) - may pull back
Risk (lower is worse)
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.0 |
| days to cover | 9.0 |
| volatility | 0.0 |
| beta | 2.7 |
| debt equity | 9.5 |
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
1.7/10data confidence 75%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 0B/3M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- MOMENTUM:6.3>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (2)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects clean gate clearance against Sentiment at 6.6 and asymmetric R:R of 0.00.
The strongest dimensions are Sentiment at 6.6, Momentum at 6.3, and Risk (lower is worse) at 5.8; the weakest are Quality at 1.6, Catalyst at 1.7, and Technical at 2.3. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Heavy Insider Buying
Trip ifNet insider activity reverses to net selling that exceeds $10 million over a 90-day window.
- P2Quality Below Engine Floor
Trip ifQuality score falls below 1.0 from the current 1.6.
- P3Technical Breakout Momentum
Trip ifMomentum score falls below 5.5, down from the current 6.7, ending the breakout.
- P4Rejected Analyst Target
Trip ifModeled upside stays below 1% for 2 consecutive quarters without a restored analyst target.
- P5Earnings Miss Pattern
Trip ifEarnings surprise stays below -10% for 2 consecutive quarters.